Invivyd (IVVD) Free Cash Flow (2021 - 2025)
Invivyd's (IVVD) quarterly Free Cash Flow came in at -$15.5 million in Q4 2025, up 48.81% on a YoY basis from -$10.4 million in Q4 2024, and down 87.33% quarter-over-quarter from -$8.2 million in Q3 2025.
Analysis
Invivyd (IVVD) Free Cash Flow (2021 - 2025) Analysis & Trends
Invivyd (IVVD) has reported Free Cash Flow for 5 consecutive years, with -$15.5 million the latest figure, recorded in Q4 2025.
- For the quarter ending Q4 2025, Free Cash Flow rose 48.81% year-over-year to -$15.5 million; the trailing twelve-month figure through Dec 2025 stood at -$58.3 million (up 65.78% YoY), and the FY2025 full-year result was -$58.3 million, up 65.78% from the prior year.
- Free Cash Flow fell to -$15.5 million in Q4 2025 per IVVD's latest filing, from -$8.2 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$8.2 million in Q3 2025 and bottomed at -$70.5 million in Q4 2021.
- Historically, Free Cash Flow has averaged -$40.4 million across 5 years, with a median of -$41.7 million in 2023.
- The sharpest annual moves came in 2022 and 2025: Free Cash Flow tumbled 135.83% in 2022, then soared 82.35% in 2025.
- Over 5 years, Free Cash Flow stood at -$70.5 million in 2021, then jumped by 32.82% to -$47.4 million in 2022, then declined by 25.09% to -$59.2 million in 2023, then surged by 49.03% to -$30.2 million in 2024, then soared by 48.81% to -$15.5 million in 2025.
- According to Business Quant data, Free Cash Flow over the past three periods registered -$15.5 million, -$8.2 million, and -$13.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 3.49 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 3.43 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.01 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 572.80 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -563.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 408.00 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Invivyd | 244.65 Mn | 84.57 Mn | 13.01 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -15.46 Mn |
| Sep 30, 2025 | -8.25 Mn |
| Jun 30, 2025 | -13.31 Mn |
| Mar 31, 2025 | -21.27 Mn |
| Dec 31, 2024 | -30.19 Mn |
| Sep 30, 2024 | -46.74 Mn |
| Jun 30, 2024 | -41.52 Mn |
| Mar 31, 2024 | -51.90 Mn |
| Dec 31, 2023 | -59.24 Mn |
| Sep 30, 2023 | -35.35 Mn |
| Jun 30, 2023 | -37.38 Mn |
| Mar 31, 2023 | -41.81 Mn |
| Dec 31, 2022 | -47.36 Mn |
| Sep 30, 2022 | -56.08 Mn |
| Jun 30, 2022 | -57.45 Mn |
| Mar 31, 2022 | -55.99 Mn |
| Dec 31, 2021 | -70.49 Mn |
| Sep 30, 2021 | -60.23 Mn |
| Jun 30, 2021 | -33.57 Mn |
| Mar 31, 2021 | -23.74 Mn |